Atara biotherapeutics presents first preclinical evaluation of ata3219, a next-generation allogeneic cd19 car t cell therapy, at the 62nd american society of hematology (ash) annual meeting

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of the first preclinical evaluation of ata3219, a next-generation, off-the-shelf, allogeneic car t-cell therapy targeting cd19, as well as data suppor
ATRA Ratings Summary
ATRA Quant Ranking